Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 22Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 12Fallopian Tube Neoplasms 11Carcinoma, Hepatocellular 9Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Mycosis Fungoides 5Leukemia, Lymphocytic, Chronic, B-Cell 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Colonic Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Sezary Syndrome 3Rectal Neoplasms 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Endometrial Neoplasms 3Cholangiocarcinoma 3

Interventions

tremelimumab 1durvalumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Immunoglobulin G 1Disulfides 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Malignant Female Reproductive System Neoplasm × Disulfides × 1 year × Clear all
NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡